Post by : Saif
Al-Najjar
Pharmaceutical giants Eli Lilly and Novo Nordisk find themselves in a heated contest to take the lead in India’s rapidly growing obesity medication market. With a vast number of potential patients and the impending entry of affordable generic alternatives, both firms are racing to solidify their standing in this lucrative healthcare arena.
By 2050, India is projected to have the second-largest population of overweight or obese individuals globally. While current obesity treatments remain pricey and mostly out-of-pocket for patients, there’s a surging demand. Experts believe the Indian obesity drug market could exceed $1 billion within two years, making it a prime target for multinational pharmaceutical companies.
Eli Lilly has taken the lead, having released its drug Mounjaro earlier than Novo Nordisk’s Wegovy. Mounjaro received approval in India for both diabetes and weight loss and swiftly captured the top position in sales within months of its debut. Healthcare professionals attribute its rapid success to its positive weight-loss outcomes and early market entry.
In response, Novo Nordisk has adopted an aggressive stance, slashing prices on Wegovy by up to 37% last November to enhance accessibility and heighten competition with Lilly. The company also introduced its diabetes treatment Ozempic in India at a reduced monthly rate. Novo’s head for India noted that recognizing the market’s price sensitivity was crucial.
The competition is poised to escalate further when patents for semaglutide, the active component in both Wegovy and Ozempic, expire in March 2026. Analysts indicate that more than 20 Indian companies plan to roll out cheaper generic versions, potentially costing about 60% less. This situation poses a heightened risk for Novo, while Lilly remains safeguarded by longer patent protections for Mounjaro extending into the next era.
Both companies are also keen on broadening their market reach. Lilly is collaborating with Cipla to launch a second variant of its drug targeting smaller towns, in addition to partnering with Apollo Hospitals to elevate awareness around obesity and diabetes. The firm is also making substantial investments in manufacturing facilities in India.
Similarly, Novo Nordisk has allied with Emcure Pharmaceuticals, launching a second semaglutide brand to enhance distribution. The company has also engaged with digital health solutions and healthcare facilities to provide patient support and promote awareness.
With direct advertising of prescription drugs being prohibited in India, both firms are initiating extensive public outreach campaigns to raise awareness of obesity as a medical condition. Initiatives through billboards, newspapers, and wellness clinics are encouraging individuals to pursue medical consultation rather than merely viewing obesity as a lifestyle choice.
As the interest in weight-loss remedies expands from urban centers to smaller towns and the middle class, the rivalry between Lilly and Novo intensifies. The resolution of this competition will have a significant impact on the treatment of obesity in India and the affordability of these transformative medications in the years to come.
English
